Education
About Us
Working with TipRanks
Follow Us
Marker Therapeutics Inc (MRKR)
NASDAQ:MRKR
MRKR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.95 - $5.99
Previous CloseN/A
Volume39.59K
Average Volume (3M)61.50K
Market Cap
$13.60M
Enterprise Value$9.11M
Total Cash (Recent Filing)$21.37K
Total Debt (Recent Filing)$485.00K
Price to Earnings (P/E)―
Beta1.65
Next Earnings
May 20, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding10,709,005
10 Day Avg. Volume40,040
30 Day Avg. Volume61,501
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.51
Price to Cash Flow (P/CF)2.30
P/FCF Ratio2.30
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.28
Enterprise Value/Ebitda-0.89
Forecast
1Y Price Target
$8.17Price Target Upside553.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Marker Therapeutics News
See All MRKR News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPreliminary data from the Phase 1 APOLLO study showed encouraging safety and efficacy results in lymphoma patients who relapsed after anti-CD19 CAR-T cell therapy.
Financial StabilityMRKR's progress from the year-end report reinforces confidence in the company’s financial future as well as its clinical progress.
FundingMRKR secured more than $13 million in non-dilutive funding to advance its lead product MT-601.
Bears Say
Financial RiskMarker Therapeutics' success is highly dependent on producing positive pivotal data for MT-601, obtaining FDA approval, and launching this experimental therapy, making the financial risk for this stock high.
Regulatory ApprovalThere is a significant risk that Marker Therapeutics may not gain FDA approval, which would prevent it from becoming a commercial company.
---
Ownership Overview
43.35% Insiders
3.02% Mutual Funds
32.34% Other Institutional Investors
18.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MRKR FAQ
What was Marker Therapeutics Inc’s price range in the past 12 months?
Marker Therapeutics Inc lowest stock price was $0.95 and its highest was $5.99 in the past 12 months.
What is Marker Therapeutics Inc’s market cap?
Marker Therapeutics Inc’s market cap is $13.60M.
When is Marker Therapeutics Inc’s upcoming earnings report date?
Marker Therapeutics Inc’s upcoming earnings report date is May 20, 2025 which is in 24 days.
How were Marker Therapeutics Inc’s earnings last quarter?
Marker Therapeutics Inc released its earnings results on Mar 31, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.497 by $0.087.
Is Marker Therapeutics Inc overvalued?
According to Wall Street analysts Marker Therapeutics Inc’s price is currently Undervalued.
Does Marker Therapeutics Inc pay dividends?
Marker Therapeutics Inc does not currently pay dividends.
What is Marker Therapeutics Inc’s EPS estimate?
Marker Therapeutics Inc’s EPS estimate is -0.22.
How many shares outstanding does Marker Therapeutics Inc have?
Marker Therapeutics Inc has 10,709,005 shares outstanding.
What happened to Marker Therapeutics Inc’s price movement after its last earnings report?
Marker Therapeutics Inc reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.497. Following the earnings report the stock price went down -3.15%.
Which hedge fund is a major shareholder of Marker Therapeutics Inc?
Currently, no hedge funds are holding shares in MRKR
---
Marker Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.17 (553.60% Upside)
$8.17 (553.60% Upside)
Hedge Fund Trend
Increased
By 237.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $35.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.13%
12-Months-Change
Fundamentals
Return on Equity
-65.81%
Trailing 12-Months
Asset Growth
28.58%
Trailing 12-Months
Company Description
Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
---
MRKR Stock 12 Month Forecast
Average Price Target
$8.17
▲(553.60% Upside)
Technical Analysis
Ibio
―
Moleculin Biotech
―
ABVC BioPharma, Inc.
―
Addex Therapeutics
―
Allarity Therapeutics, Inc.
―
Best Analysts Covering MRKR
1 Year
1 Year Success Rate
2/4 ratings generated profit
1 Year Average Return
-0.80%
reiterated a buy rating 27 days ago
Copying Stephen Brozak's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -0.80% per trade.
---